Bionano Genomics announced its participation at the Cancer Genomics Consortium, CGC, 2023 Annual Meeting with a broad range of content covering the utility of optical genome mapping, OGM, for solid tumor and hematological malignancy cancer research, including scientific platform and poster presentations from Bionano and a panel discussion featuring esteemed researchers from across the cancer genomics landscape. As part of a sponsored spotlight panel, Bionano’s chief medical officer, Dr. Alka Chaubey, will host a discussion titled “Unleashing Genomic Insights That Matter with Optical Genomic Mapping: An Interactive Panel Discussion,” featuring cancer genomics experts Dr. Ravindra Kolhe, Dr. Yassmine Akkari, Dr. Susan Crocker, and Dr. Sachin Jadhav, from HCG Network. Thirteen separate scientific presentations highlighting OGM as a novel technique in cancer research will be given at the conference.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BNGO:
- Bionano Announces Presentation of Optical Genome Mapping (OGM) Utility Across Cancer Research Applications at the Cancer Genomics Consortium (CGC) 2023 Annual Meeting
- Bionano Genomics price target raised to $10 from $2 at BTIG
- Bionano Genomics reports Q2 revenue $8.7M, consensus $8.29M
- Bionano Reports Second Quarter 2023 Results and Highlights Recent Business Progress
- Bionano Genomics options imply 13.1% move in share price post-earnings